Rome founders can combine local venture teams, a Lazio public-capital ecosystem and national specialist investors. The best first wave depends on whether the business is forming, validating a technology or expanding commercially. Choose the vehicle before writing the pitch.
Compare 16 provider families, including 7 documented local or regional routes. Start with the decision framework, use the comparison to screen candidates and save the evidence in the worksheet before you approach anyone.
Choose the Rome and Lazio capital lane that fits now
| Your situation | Research first | Prepare or clarify |
|---|---|---|
| Early applied-AI company | Compare Pi Campus, the relevant Zest route and suitable wider technology funds. | Explain the product, industry user and first proof point. |
| Healthcare or life-sciences development | Compare Angelini, Panakès and the appropriate Sofinnova strategy. | Bring product-appropriate scientific evidence and a development milestone. |
| Space, climate, health or digital technology | Identify the relevant Primo strategy. | Different specialist vehicles require different technical and commercial evidence. |
| Regional direct-capital opportunity | Research Lazio Innova’s current direct-company route. | Separate direct funds from fund allocations, grants and credit. |
| Italian founder building globally | Compare Vento, IAG and the relevant national firms. | Founder connections and a Rome office are different geographic screens. |
Choose a small first wave you can research properly. Record one reason for fit, one relevant proof point and the next unanswered question for each investor. Move a name out of the active queue when the stage, sector or geographic conditions do not fit.
Compare 16 local and wider investor routes
The connection column distinguishes a documented city or regional route from a wider mandate. It does not imply that every provider has an office here. Initial investment stages and follow-on support are different. This selective list is unranked; each provider family counts once.
| Investor or network | Connection | Entry-stage distinction | Company focus |
|---|---|---|---|
| United Ventures | Wider route: Italian technology; global company ambition | Confirm the relevant fund and entry round | Technology businesses |
| P101 | Wider route: Italian and European technology ecosystem | Fund-specific; confirm commercial readiness | Digital and technology companies |
| Primo Capital | Local / regional: Rome-linked strategy platform; wider Italian ecosystem | Climate, space, health and digital vehicles differ | Climate, space, health and digital technology |
| Vertis | Wider route: Innovative Italian companies | Startup, scale-up and innovative SME vehicles | Technology and innovative industry |
| CDP Venture Capital | Local / regional: Rome-based national platform | Pre-seed onward; direct and indirect routes differ | Technology and strategic industrial sectors |
| 360 Capital | Wider route: Europe; Milan and Paris teams | Pre-seed to Series B | Deep tech, climate and digital-first businesses |
| Panakès Partners | Local / regional: Rome contact listed at Zest; wider European remit | Early-stage; product-specific development | Medical and life-sciences innovation |
| Sofinnova Partners | Wider route: European and international specialist strategies | Company creation through later stages; separate funds | Biopharma, medtech, digital medicine and industrial biotech |
| BlackSheep | Wider route: European AI-native companies | Seed to Series B | Vertical AI and industry workflows |
| Italian Angels for Growth | Wider route: Italian startup ecosystem | Early-company funding; member-specific | Innovative companies across sectors |
| The Techshop | Wider route: Italian B2B digital ecosystem | Seed | B2B digital businesses |
| Zest | Local / regional: Rome location; wider Italian startup ecosystem | Early-stage investment; programme-specific | Technology startup development |
| Angelini Ventures | Local / regional: Rome-based group; global investment remit | Vehicle- and product-specific | Biotech and health technology |
| Pi Campus | Local / regional: Rome campus; AI-applied startups worldwide | Early stage | Applied AI and technology in established industries |
| Lazio Innova: direct-capital routes | Local / regional: Lazio regional activity; programme-specific | Direct funds and current programmes differ | Innovative startups and regional company development |
| Vento | Wider route: Italian founders globally; Turin base, not Rome office | Pre-seed and seed | Across technology sectors |
Which Lazio route actually invests in the company?
Lazio Innova’s current venture portal distinguishes direct-company investment from fund-of-funds activity and publishes newer initiatives alongside historic funds. Start with the current direct-capital route and check its conditions and timing.
A programme announced for fund managers is not automatically a startup application. Likewise, grants, credit support and business services do not become equity investors. Record the specific vehicle and who makes the investment decision before adding it to the active queue.
Choose the scientific specialist before the local generalist
Rome’s healthcare and research connections can support a specialist financing story. Explain the underlying evidence, the intended product and the next milestone. A therapeutic programme, a device and a health-software product are not interchangeable healthcare investments.
Primo, Panakès, Angelini and Sofinnova publish different strategies. Use those distinctions to decide which team should evaluate the company rather than sending the same general deck to every health-related investor.
Keep the national guide central and the city job specific
The national Italy guide remains the broad starting point. This Rome guide adds the choice among local company-building and AI routes, Lazio direct capital and specialist strategies. Wider investors are labelled accordingly; an Italian-founder mandate does not imply a Rome office.
In the shortlist, write down one reason each provider fits now and one unresolved question. A later-stage or unrelated strategy belongs outside the first wave even when its brand is familiar.
16 investors and networks to research
1. United Ventures
Technology venture firm. United Ventures backs technology entrepreneurs with a scalable industry-changing product. For a Turin team, the useful first step is to connect its technical advantage with a business model that can travel beyond the local industrial market. Its founder proposal route is distinct from fund-investor enquiries.
Approach: Read the investment FAQ, then submit the founder proposal. Official United Ventures information.
2. P101
Technology investment manager. P101 operates several fund generations rather than one universal startup offer. Identify the appropriate investment team and explain the product, adoption and commercial milestone. Its current investment activity is a research starting point, not evidence that every company resembling a portfolio business qualifies.
Approach: Use the published Contact route. Official P101 information.
3. Primo Capital
Specialist venture platform. Primo separates climate, space, health and digital strategies. A space component and an enterprise software product require different evidence even when both are developed in Turin. Choose the vehicle first and explain the development milestone. Primo Ventures and current Primo Capital branding are one manager here.
Approach: Use the appropriate strategy and Contact us information. Official Primo Capital information.
4. Vertis
Venture and growth investment manager. Vertis invests across startup and later-company development through distinct funds. A Turin industrial company should identify whether its round finances research commercialization, a repeatable product or expansion. Bring a milestone plan and the relevant technical and customer evidence rather than treating all of those stages as seed.
Approach: Use the published firm contact. Official Vertis information.
5. CDP Venture Capital
Direct and indirect venture platform. CDP combines direct-company funds, technology transfer, acceleration and investment into other funds. Only a matching founder-facing route belongs in your active queue. A public programme headline is not an application to all CDP capital, and an indirect fund allocation is not a direct startup cheque.
Approach: Identify a direct company-facing fund or active programme. Official CDP Venture Capital information.
6. 360 Capital
European technology venture firm. 360 publishes an early-stage European remit from pre-seed through Series B. That makes the actual stage and technology thesis more useful than office proximity. Explain the product advantage and the next proof point, then use the dedicated pitch route instead of an unrelated portfolio-company contact.
Approach: Use Pitch now. Official 360 Capital information.
7. Panakès Partners
Life-sciences venture firm. Panakès is a specialist medical and life-sciences route. A team should explain the unmet need, scientific or product evidence and development plan. Do not substitute a general healthcare-market slide for a clear account of what the product must demonstrate next.
Approach: Use Submit a project. Official Panakès Partners information.
8. Sofinnova Partners
Life-sciences investment firm. Sofinnova spans several stages and scientific disciplines through different strategies. A therapeutic programme and a sustainable industrial process should not be pitched as interchangeable life-sciences opportunities. Identify the appropriate team and the experiment or commercial milestone that reduces the most important risk.
Approach: Use the project or Contact Us route for the relevant strategy. Official Sofinnova Partners information.
9. BlackSheep
Vertical-AI venture firm. BlackSheep’s current thesis is vertical AI, with a new-fund announcement dated November 12, 2026. A Turin company should identify the industry buyer and explain how its AI changes a consequential workflow. Generic AI branding is less useful than evidence of a durable product advantage.
Approach: Use Submit a Pitch in Contacts. Official BlackSheep information.
10. Italian Angels for Growth
Angel-investor community. IAG combines members’ capital, operating experience and professional relationships. It is a community of investors rather than one automatic pooled-fund decision. Prepare a concise company case and be clear about the expertise needed alongside capital, then follow the startup selection process.
Approach: Use the Startup route. Official Italian Angels for Growth information.
11. The Techshop
Seed venture firm. The Techshop explicitly emphasizes seed-stage B2B digital companies. A Turin software company should make the business buyer, product roadmap and evidence of demand easy to understand. Its general site contact asks founders to use the dedicated investment route, so keep the proposal out of unrelated enquiries.
Approach: Use the dedicated investment-proposal page. Official The Techshop information.
12. Zest
Venture investment and company-development platform. Zest lists a Turin location alongside Rome and Milan and combines investment with startup development and innovation services. Choose the investment route rather than assuming a corporate-service engagement includes capital. Predecessor brands and individual programmes do not become additional independent investors in this list.
Approach: Use the investment scouting and Contact us information. Official Zest information.
13. Angelini Ventures
Healthcare venture investor. Angelini Ventures builds and invests in biotech and health-technology companies. Explain the unmet need, development evidence and path into care. Its corporate context can bring relevant capabilities, but a potential commercial relationship and an investment are distinct decisions.
Approach: Use the published company contact. Official Angelini Ventures information.
14. Pi Campus
Early-stage technology investor. Pi Campus explicitly combines early investment with workspace and mentoring and describes a worldwide applied-AI remit. Explain the technology, user and industry problem. A campus or educational programme is not the same as its seed-investment decision; use the dedicated funding route.
Approach: Use apply to get funded. Official Pi Campus information.
15. Lazio Innova: direct-capital routes
Regional public investment platform. Lazio Innova separates direct-company holdings from fund-of-funds strategies, grants and credit support. Its current venture portal includes newer 2026 initiatives as well as historic funds. Identify the actual direct-capital vehicle and current company requirements; a fund-manager allocation is not a startup application.
Approach: Select the current direct-company route; check timing and conditions. Official Lazio Innova: direct-capital routes information.
16. Vento
Early-stage venture firm. Vento’s fund backs early-stage Italian founders across geographies. That founder connection is different from requiring every company to remain in Turin. Reef is a separate venture-building programme for people before team and idea, while Wave is an event. Count the fund family once and choose the route matching your actual company state.
Approach: Use the Fund information and founder contact. Official Vento information.
A Rome health-software team chooses different evidence packs
Fictional worked example. A Rome team has a health-workflow prototype and interviews with potential business buyers. It is not developing a therapeutic and has not yet validated a repeatable commercial model.
| Candidate | Next action | Why it changes the decision |
|---|---|---|
| Pi Campus / Zest | Explain the applied technology and buyer problem. | Early product evidence supports a different conversation from mature growth. |
| Angelini / Panakès | Establish whether the actual health-technology thesis fits. | A healthcare setting alone is not enough. |
| Lazio Innova | Identify the current direct-company vehicle. | Regional support includes mechanisms other than equity. |
| Therapeutics-only strategies | Exclude unless the scientific product genuinely changes. | Do not force a software company into a biological-development thesis. |
The aim is a more coherent queue, not the largest possible one. Connect the proposed round with an achievable milestone using the round-size planning worksheet.
Build your Rome investor-fit worksheet
Use one card for each provider and strategy. It works in a document, spreadsheet or your Finta research notes. Keep facts, expectations and questions in separate fields.
INVESTOR FIT CARD: ROME
Company, current evidence and next funding milestone: [authorised facts]
Rome/Lazio connection: office / operations / research / founder
Actual vehicle and current direct-company decision-maker
Product lane: software-AI / space / health / scientific / climate
Programme timing and current company conditions
Investor and specific vehicle: [current name; avoid rebrand duplicates]
Official stage, sector and geographic criteria: [URL; date]
Fit evidence: [what matches; not just a portfolio resemblance]
Mismatch or open question: [the unresolved issue]
Approach route: [founder form / network selection / general enquiry]
Relationship context: [known person; permission to ask; or public route]
Lead/co-investment status: [unknown / conditional / confirmed]
Owner, next action and follow-up date: [person; action; date]Bring the shortlist into Finta to keep investor research, relationship context and follow-up connected. Aurora can help organise the context and prepare a next move for your review. You stay in control of the approach and information shared.
Review your shortlist with Aurora, Claude or Codex
Paste the prompt with the public sources and company information you are authorised to use. Check its output against the sources before acting.
Help me research investor fit for a Rome startup.
Company, location, current evidence and funding milestone: [authorised facts]
Candidates and official sources: [names, URLs and research dates]
Separate local offices, regional operating requirements and wider investment eligibility.
Check the specific vehicle, initial stage, sector, company conditions and public approach route.
Keep university programmes, angel networks, direct equity, grants and commercial partnerships distinct.
Count each manager or rebrand once. Do not assume a portfolio investment proves current eligibility.
Return a table: source, fit evidence, mismatch, unknown, next question and owner.
Flag missing or contradictory evidence instead of filling gaps.
Suggest a short first research wave and explain exclusions.
Do not contact anyone, submit forms or share confidential information.Keep the wider fundraising process connected with the pre-seed guide, Seed Fundraising Comprehensive Guide and investor-prospecting workflow. For national coverage, see the Italy investor guide.
Methodology and research date
By Finta Editorial Team. Official investor, public-institution and company materials reviewed November 13, 2026, with source-dated prior research used for discovery. 16 provider families are included: 7 documented local or regional routes and 9 wider mandates. Angel networks are identified as networks, not pooled funds. Company-building and strategic investment routes are labelled separately.
Startup Genome’s 2026 Emerging Ecosystems ranking informed city selection; it is not an investor ranking or endorsement. Current official materials support the profiles. A published thesis is not a promise of available capital, current intake or an investment outcome. Confirm open questions directly.
Not counted or kept separate:
- LVenture, predecessor Zest brands and individual accelerator programmes are not counted as separate managers.
- Lazio fund-of-funds allocations, grants and credit support are kept separate from direct-company investment.
General information, not personalised financial, legal or tax advice. Programme and company criteria are research filters, not an eligibility ruling. The cover is an editorial ecosystem illustration, not a map of investor offices or actual financing flows.